A team of Argentinian scientists is making significant strides in the rapid diagnosis of Hepatitis E, a viral infection often overlooked, particularly in regions where access to advanced medical facilities is limited. Researchers in La Plata are developing a portable, digital diagnostic tool leveraging cutting-edge technologies like graphene sensors, nanoantibodies, and artificial intelligence. This innovation promises faster, more accurate results and could dramatically improve public health outcomes, especially as Hepatitis E is increasingly recognized as a zoonotic disease – transmissible from animals to humans.
The development of this diagnostic kit addresses a critical need. Hepatitis E, primarily spread through contaminated water, is frequently underdiagnosed. The ability to quickly and accurately identify the virus, even in remote settings, is a major step forward. The project, spearheaded by the ViroSensAr network, builds on a foundation of collaborative research and technological expertise within Argentina, combining the strengths of several key institutions and a burgeoning bioelectronics startup. This portable test represents a significant advancement in point-of-care diagnostics, potentially revolutionizing how this often-silent threat is managed.
The research, published in December 2025 in the peer-reviewed scientific journal ACS Sensors, details the creation of this digital diagnostic kit. The device’s core innovation lies in its ability to detect the presence of the Hepatitis E virus (HEV) using a combination of advanced materials and intelligent algorithms. This technology not only offers speed and convenience but too the potential for increased accuracy compared to traditional diagnostic methods. The team’s success highlights the growing role of artificial intelligence in medical diagnostics and the potential for localized innovation to address global health challenges.
A Collaborative Effort Rooted in Argentinian Science
At the heart of this project is the ViroSensAr network, established in 2023 through an initiative of the Argentinian Ministry of Science, Technology and Innovation. This network brings together researchers from the National Scientific and Technical Research Council (CONICET) and several leading universities, fostering a collaborative environment for developing rapid and portable biosensors for viral infections. Key participating institutions include the Theoretical and Applied Physical-Chemical Research Institute (INIFTA, CONICET-UNLP) in La Plata, the Institute of Physical Chemistry of Materials, Environment and Energy (INQUIMAE, CONICET-UBA) in Buenos Aires, and the Higher Institute of Biological Research (INSIBIO, CONICET-UNT) in Tucumán. CONICET plays a central role in coordinating and supporting this vital research.
The project also benefits from the expertise of Gisens Biotech, a La Plata-based startup specializing in bioelectronics and nanotechnology. Gisens Biotech, which also has a presence in the United States, contributes its innovative capabilities in sensor development and manufacturing to the ViroSensAr network. This public-private partnership exemplifies a successful model for translating scientific research into practical applications with real-world impact. Omar Azzaroni, a CONICET researcher at INIFTA and coordinator of ViroSensAr, emphasized the network’s focus on “undetended and important health diseases” as the driving force behind prioritizing Hepatitis E.
How the Innovative Diagnostic Device Works
The diagnostic device utilizes a chip sensor constructed from graphene, a single-layer carbon material renowned for its exceptional conductivity and sensitivity. This graphene sensor is functionalized with nanoantibodies – tiny proteins derived from camelids like llamas and alpacas – that are specifically designed to recognize a key marker of the Hepatitis E virus, known as ORF2. According to researcher Esteban Piccinini, these nanoantibodies exhibit a high degree of precision in identifying ORF2. The study published in ACS Sensors details the process of functionalizing graphene field-effect transistors (GFETs) with these llama-derived nanobodies.
When the nanoantibodies bind to the ORF2 protein, the sensor detects this interaction and converts it into a digital signal, providing a rapid and accurate diagnosis. A significant recent advancement involved incorporating machine learning algorithms to enhance the system’s precision. This integration improved the test’s sensitivity and specificity, moving it from an initial 89% sensitivity and 69% specificity to levels approaching 100%. This improvement is crucial for ensuring reliable diagnostic results and minimizing false positives or negatives.
Hepatitis E: An Underestimated Global Health Concern
The World Health Organization (WHO) estimates that millions of Hepatitis E cases occur globally each year. The WHO provides comprehensive information on Hepatitis E, outlining its transmission, symptoms, and prevention. The infection is primarily transmitted through contaminated water, but can also spread through contact with animals, particularly pigs and wild boars. In Argentina, while considered a country with low circulation of the virus, experts caution that the disease may be underdiagnosed due to its often-mild or asymptomatic nature and the similarity of its symptoms to other forms of hepatitis.
The latest diagnostic device offers a key advantage: it requires only a small blood sample obtained through a finger prick, eliminating the need for a traditional venipuncture. This makes testing more accessible, particularly in smaller healthcare facilities or rural areas lacking sophisticated equipment and specialized personnel. The portability and ease of leverage of the device could significantly expand access to Hepatitis E testing, leading to earlier diagnosis and improved patient outcomes.
Beyond Detection: Quantifying Viral Load for Improved Treatment
A particularly valuable feature of this new test is its ability to not only detect the presence of the virus but also to measure the exact amount of antigen in the blood. This quantitative data is especially important for patients who develop chronic Hepatitis E infections, as it allows clinicians to monitor the effectiveness of treatment and adjust medication accordingly. Understanding the viral load provides crucial insights into the progression of the disease and helps guide personalized treatment strategies.
The biosensor’s ability to detect and quantify HEV ORF2 proteins with high sensitivity – achieving amplitudes as high as 22.5 mV and a limit of detection in the nanomolar range, as detailed in the ACS Sensors publication – represents a significant leap forward in diagnostic capabilities. The researchers validated the graphene interfacial transduction by correlating antigen concentration with GFET response, further solidifying the reliability of the technology.
Key Takeaways
- Rapid and Accessible Diagnosis: The portable device offers quick Hepatitis E detection using a simple finger prick, ideal for resource-limited settings.
- Advanced Technology: Combining graphene sensors, nanoantibodies, and artificial intelligence enhances accuracy and reliability.
- Zoonotic Disease Focus: Addresses the growing concern of Hepatitis E as a virus transmissible from animals to humans.
- Quantitative Viral Load Measurement: Provides valuable data for monitoring treatment effectiveness in chronic infections.
If clinical application is realized, this development could become a crucial tool for improving the early diagnosis of Hepatitis E, combining cutting-edge scientific research, innovative technology, and local development driven from La Plata. The ViroSensAr network is continuing to refine the technology and explore potential partnerships for commercialization and widespread implementation. The next steps involve larger-scale clinical trials to validate the device’s performance in real-world settings and to obtain regulatory approvals for its use.
Researchers are expected to present further findings at the International Symposium on Hepatitis Viruses in September 2026. We encourage readers to share this article and engage in the conversation about the importance of accessible and accurate diagnostic tools in combating global health threats.
Related reading